<DOC>
	<DOCNO>NCT01845311</DOCNO>
	<brief_summary>The RESTORE II clinical trial intend assess safety performance ReZolve2 Bioresorbable Coronary Scaffold native coronary artery .</brief_summary>
	<brief_title>ReZolve2 Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>Primary Patient evidence myocardial ischemia positive functional study Patient normal CKMB Target lesion visually estimate stenosis ≥50 % &lt; 100 % Target lesion locate native coronary artery average reference vessel diameter ≥ 2.75mm ≤ 3.3mm Target lesion length must ≤ 14mm Primary Patient experience myocardial infarction ( CKMB Troponin &gt; 5 X ULN ) within 72 hour procedure Patient leave ventricular ejection fraction &lt; 30 % Patient unprotected l main coronary disease ≥50 % stenosis The target vessel totally occlude ( TIMI Flow 0 1 ) Target lesion involve bifurcation ( lesion side branch ≥ 2.0 mm diameter contain ≥ 50 % stenosis ) . Target lesion locate within bypass graft Target lesion possible definite thrombus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>